You are here

Novartis

8 More Big Pharma Events in 2019 You Don't Want to Miss

Motley Fool

Mon, 07/22/19 - 09:44 am

Bristol-Myers Squibb

Novartis licenses out early antiviral work to Gilead

Fierce Biotech

Fri, 07/19/19 - 10:51 am

Gilead Sciences

Novartis’ sunny Sandoz forecast is at odds with the reality of the US generics market: analysts

Fierce Pharma

Fri, 07/19/19 - 10:47 am

Payers, patients coming on board for Novartis’ Zolgensma

BioCentury

Thu, 07/18/19 - 05:58 pm

Novartis, aiming to clean up its rep, sets aside $700M for kickback settlement

Fierce Pharma

Thu, 07/18/19 - 11:41 am

Novartis Earnings Top; Swiss Drug Giant Soars

Investors Business Daily

Thu, 07/18/19 - 10:10 am

Novartis secures speedy review for sickle cell drug

Biopharma Dive

Tue, 07/16/19 - 12:05 pm

sickle cell disease

Gilead and Novartis Seek to Expand What FDA Considers as Real-World Data and Real-World Evidence

RAPS.org

Mon, 07/15/19 - 07:06 pm

Gilead Sciences

real world data

real world evidence

Novartis trims again with $390m drugs sale to Recordati

Pharmaforum

Mon, 07/15/19 - 09:55 am

Emgality-maker Lilly courts payers with new migraine ER data

Fierce Pharma

Fri, 07/12/19 - 12:22 pm

cluster headache

Teva Pharmaceutical

Amgen, Novartis BACE Inhibitor Joins List of Failed Alzheimer’s Drugs

Xconomy

Thu, 07/11/19 - 11:15 pm

Alzheimer's disease

BACE inhibitors

Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations

BioSpace

Thu, 07/11/19 - 09:52 am

Mirati Therapeutics

Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap

Fierce Pharma

Wed, 07/10/19 - 11:34 am

Adamis Pharmaceuticals

Roche, Merck, Novartis and others hike prices on 83 meds starting in July: analyst

Fierce Pharma

Tue, 07/9/19 - 11:57 am

Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma: analysts

Fierce Pharma

Wed, 07/3/19 - 10:38 am

Sandoz launches oncology generic gefitinib in 13 EU countries

Pharmaceutical Business Review

Wed, 07/3/19 - 09:57 am

metastatic non-small cell lung cancer

Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra

Pharmaceutical Business Review

Tue, 07/2/19 - 10:24 am

hdry eye disease

Swiss firm Novartis has said that it did not send chemicals that could be used to make chemical weapons to Syria

Pharmafile

Mon, 07/1/19 - 07:42 pm

biological weapons

Threats to Spinraza are mounting, but Biogen still has cards to play

EP Vantage

Mon, 07/1/19 - 07:25 pm

Novartis wins Gilenya reprieve as judge blocks generics, for now

Yahoo/Reuters

Tue, 06/25/19 - 09:20 am

multiple sclerosis

Pages